Much has been learned about how cells enter lymphoid tissues. But how do they leave?
Sphingosine-1-phosphate (S1P) has emerged over the past decade as a central mediator of …

Fingolimod is the first oral disease-modifying therapy approved for relapsing forms of
multiple sclerosis (MS). Following phosphorylation in vivo, the active agent, fingolimod …

The eye, as currently viewed, is neither immunologically ignorant nor sequestered from the
systemic environment. The eye utilises distinct immunoregulatory mechanisms to preserve …

The moniker lysophospholipid incorporates two broad families of membrane-derived lipids:
the glycerophospholipids and the sphingolipids. 1 Primary representatives of these two arms …

PURPOSE: To report outcomes of ophthalmic evaluations in clinical studies of patients
receiving fingolimod (Gilenya; Novartis Pharma AG, Basel, Switzerland) for multiple …

Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of
sight loss in the working population. Most uveitis seen in Western countries is noninfectious …

Sphingolipids have emerged as bioactive lipids involved in the regulation of many
physiological and pathological processes. In the retina, they have been established to …

Fingolimod, also known as FTY720, has recently been approved by the regulatory
authorities in the US, EU, Australia, Russia, among others, for the treatment of relapsing …

Sphingolipids are a ubiquitous membrane lipid present in every cell and found most
abundantly in neural tissues. Disorders such as Tay-Sachs or Niemann-Pick disease are the …

Inflammation occurs in response to tissue injury and invasion of microorganisms and is
carried out by the innate and adaptive immune systems, which are regulated by numerous …